Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Specific immunotherapy in allergic asthma].

K-Ch Bergmann1

  • 1Allergie- und Asthma-Klinik Bad Lippspringe. aak-bergmann@t-online.de

Pneumologie (Stuttgart, Germany)
|February 13, 2003
PubMed
Summary

Specific immunotherapy effectively treats allergic asthma by normalizing the TH2 cytokine phenotype. It is recommended for mild asthma cases with proven IgE-mediated sensitization to common allergens.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Laryngo- rhino- otologie·2021
Same author

[DGP-Newsletter March 2011].

Pneumologie (Stuttgart, Germany)·2011
Same author

[Guidelines for diagnosing extrinsic allergic alveolitis (hypersensitivity pneumonitis) (German Extrinsic Allergic Alveolitis Study Group)].

Pneumologie (Stuttgart, Germany)·2007
Same author

[Efficacy and safety of sublingual immunotherapy--a detailed analysis].

Pneumologie (Stuttgart, Germany)·2006
Same author

[Efficacy and safety of sublingual immunotherapy].

Pneumologie (Stuttgart, Germany)·2005
Same author

[44th Congress of the German Society for Pneumology, Mar 26-29, 2003 and Munich. Recent findings from and pneumology section of the Society]].

Pneumologie (Stuttgart, Germany)·2003

Area of Science:

  • Immunology and Respiratory Medicine

Context:

  • Asthma is a chronic airway inflammatory disease driven by immune dysregulation, particularly the T-helper 2 (TH2) cytokine phenotype.
  • Current allergic asthma management includes allergen avoidance, pharmacotherapy, immunotherapy, and patient education.

Purpose:

  • To evaluate the efficacy of allergen-specific immunotherapy in managing allergic asthma.
  • To assess immunotherapy's role in normalizing the TH2 cytokine phenotype and improving clinical outcomes.

Summary:

  • Specific immunotherapy normalizes the elevated TH2 cytokine phenotype in patients with IgE-mediated sensitization to allergens like pollens, dust mites, and pet dander.
  • Randomized controlled trials demonstrate immunotherapy's effectiveness in reducing bronchial hyperreactivity, asthma symptoms, and medication needs.
  • Patient selection is crucial, balancing efficacy against potential side effects, with a recommendation for mild asthma cases managed by allergology-trained pneumologists.

Impact:

  • Immunotherapy offers a targeted approach to allergic asthma, potentially altering disease trajectory by addressing underlying immune mechanisms.
  • This treatment can lead to significant symptom improvement and reduced reliance on conventional asthma medications.
  • Optimizing patient selection ensures safe and effective application of immunotherapy, enhancing quality of life for mild asthma patients.

Related Experiment Videos